221 related articles for article (PubMed ID: 27589687)
1. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.
Park H; Garrido-Laguna I; Naing A; Fu S; Falchook GS; Piha-Paul SA; Wheler JJ; Hong DS; Tsimberidou AM; Subbiah V; Zinner RG; Kaseb AO; Patel S; Fanale MA; Velez-Bravo VM; Meric-Bernstam F; Kurzrock R; Janku F
Oncotarget; 2016 Oct; 7(41):67521-67531. PubMed ID: 27589687
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.
Zibelman M; Wong YN; Devarajan K; Malizzia L; Corrigan A; Olszanski AJ; Denlinger CS; Roethke SK; Tetzlaff CH; Plimack ER
Invest New Drugs; 2015 Oct; 33(5):1040-7. PubMed ID: 26091915
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.
Janku F; Park H; Call SG; Madwani K; Oki Y; Subbiah V; Hong DS; Naing A; Velez-Bravo VM; Barnes TG; Hagemeister FB; Falchook GS; Karp DD; Wheler JJ; Piha-Paul SA; Garrido-Laguna I; Shpall EJ; Fayad LE; Neelapu SS; Meric-Bernstam F; Kurzrock R; Fanale MA
Clin Cancer Res; 2020 Nov; 26(21):5579-5587. PubMed ID: 33055173
[TBL] [Abstract][Full Text] [Related]
4. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
Hummel TR; Wagner L; Ahern C; Fouladi M; Reid JM; McGovern RM; Ames MM; Gilbertson RJ; Horton T; Ingle AM; Weigel B; Blaney SM
Pediatr Blood Cancer; 2013 Sep; 60(9):1452-7. PubMed ID: 23554030
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD
Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954
[TBL] [Abstract][Full Text] [Related]
6. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.
Mahalingam D; Mita M; Sarantopoulos J; Wood L; Amaravadi RK; Davis LE; Mita AC; Curiel TJ; Espitia CM; Nawrocki ST; Giles FJ; Carew JS
Autophagy; 2014 Aug; 10(8):1403-14. PubMed ID: 24991835
[TBL] [Abstract][Full Text] [Related]
7. Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination.
Carr RM; Duma N; McCleary-Wheeler AL; Almada LL; Marks DL; Graham RP; Smyrk TC; Lowe V; Borad MJ; Kim G; Johnson GB; Allred JB; Yin J; Lim VS; Bekaii-Saab T; Ma WW; Erlichman C; Adjei AA; Fernandez-Zapico ME
Pancreatology; 2020 Sep; 20(6):1115-1122. PubMed ID: 32778368
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
Dasari A; Gore L; Messersmith WA; Diab S; Jimeno A; Weekes CD; Lewis KD; Drabkin HA; Flaig TW; Camidge DR
Invest New Drugs; 2013 Feb; 31(1):115-25. PubMed ID: 22415798
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies.
Trivedi ND; Armstrong S; Wang H; Hartley M; Deeken J; Ruth He A; Subramaniam D; Melville H; Albanese C; Marshall JL; Hwang J; Pishvaian MJ
Cancer Med; 2021 Mar; 10(6):1944-1954. PubMed ID: 33638305
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.
Kyriakopoulos CE; Braden AM; Kolesar JM; Eickhoff JC; Bailey HH; Heideman J; Liu G; Wisinski KB
Invest New Drugs; 2017 Jun; 35(3):290-297. PubMed ID: 28004284
[TBL] [Abstract][Full Text] [Related]
11. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.
Fouladi M; Park JR; Stewart CF; Gilbertson RJ; Schaiquevich P; Sun J; Reid JM; Ames MM; Speights R; Ingle AM; Zwiebel J; Blaney SM; Adamson PC
J Clin Oncol; 2010 Aug; 28(22):3623-9. PubMed ID: 20606092
[TBL] [Abstract][Full Text] [Related]
12. NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma.
Molina AM; van der Mijn JC; Christos P; Wright J; Thomas C; Dutcher JP; Nanus DM; Tagawa ST; Gudas LJ
Invest New Drugs; 2020 Oct; 38(5):1383-1389. PubMed ID: 31898184
[TBL] [Abstract][Full Text] [Related]
13. Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours.
Martin-Liberal J; Gil-Martín M; Sáinz-Jaspeado M; Gonzalo N; Rigo R; Colom H; Muñoz C; Tirado OM; García del Muro X
Br J Cancer; 2014 Aug; 111(5):858-65. PubMed ID: 25003665
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.
Schelman WR; Traynor AM; Holen KD; Kolesar JM; Attia S; Hoang T; Eickhoff J; Jiang Z; Alberti D; Marnocha R; Reid JM; Ames MM; McGovern RM; Espinoza-Delgado I; Wright JJ; Wilding G; Bailey HH
Invest New Drugs; 2013 Dec; 31(6):1539-46. PubMed ID: 24114121
[TBL] [Abstract][Full Text] [Related]
15. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
Quek R; Wang Q; Morgan JA; Shapiro GI; Butrynski JE; Ramaiya N; Huftalen T; Jederlinic N; Manola J; Wagner AJ; Demetri GD; George S
Clin Cancer Res; 2011 Feb; 17(4):871-9. PubMed ID: 21177764
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.
Oki Y; Buglio D; Fanale M; Fayad L; Copeland A; Romaguera J; Kwak LW; Pro B; de Castro Faria S; Neelapu S; Fowler N; Hagemeister F; Zhang J; Zhou S; Feng L; Younes A
Clin Cancer Res; 2013 Dec; 19(24):6882-90. PubMed ID: 24097867
[TBL] [Abstract][Full Text] [Related]
17. Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.
Gadgeel SM; Lew DL; Synold TW; LoRusso P; Chung V; Christensen SD; Smith DC; Kingsbury L; Hoering A; Kurzrock R
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1089-96. PubMed ID: 24057042
[TBL] [Abstract][Full Text] [Related]
18. Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors.
Amin M; Gao F; Terrero G; Picus J; Wang-Gillam A; Suresh R; Ma C; Tan B; Baggstrom M; Naughton MJ; Trull L; Belanger S; Fracasso PM; Lockhart AC
Am J Clin Oncol; 2021 Sep; 44(9):443-448. PubMed ID: 34310349
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
[TBL] [Abstract][Full Text] [Related]
20. A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma.
Subbiah V; Brown RE; McGuire MF; Buryanek J; Janku F; Younes A; Hong D
Oncotarget; 2014 Jan; 5(1):95-102. PubMed ID: 24395633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
